Skip to main content
Signal8

BioInvent International AB (publ) (BOVNF)

Sector: Biotechnology

Industry: Biotechnology

BioInvent International AB (publ) logo

BioInvent International AB (publ)

OTC:BOVNFHealthcare
CLOSED
Mkt Cap$18.41M
EV-
Float47.51M
O/S65.8M
VOL650 sh
$ Vol$182
RVOL0.18×
Inst Own-
SI<0.1%
Net Cash/Sh-
EarningsMar 4 · in 4mo
Dilution
BioInvent International AB (publ) logoOTC:BOVNFClosed
Historical Data
DateOpenHighLowCloseVolume
Nov 9, 20260.27980.27980.27980.2798650
Nov 6, 20260.35940.35940.35940.35942,500
Nov 3, 20260.39950.39950.39950.39952,500
Nov 2, 20260.54860.54860.44410.44417,000
Oct 29, 20260.75300.92990.60970.60975,000
Analyst Coverage
No analyst coverage for this companyNo ratings, price targets, or covering firms on file.
About

BioInvent International AB (publ) is a clinical-stage biotechnology company primarily focused on identifying, exploring, and engineering immunomodulatory antibodies to combat various forms of cancer.

The company's activities extend globally, reaching markets in Sweden, across Europe, the United States, Japan, and other international regions.

Its leading investigational compound is BI-1206, which is being developed to address both non-Hodgkin lymphoma and a range of solid tumors. Beyond this flagship program, BioInvent is advancing a diverse pipeline of therapeutic candidates. These include agents designed to target tumor-associated myeloid cells and cancer-associated regulatory T cells, which play a vital role in regulating the immune system.

The company's portfolio also features BT-001 for solid tumor indications, as well as BI-1808 and BI-1910 – both anti-TNFR2 antibodies specifically intended for the treatment of solid tumors and cutaneous T-cell lymphoma. To further its development initiatives, BioInvent has established several key collaborations.

It maintains a strategic alliance with Pfizer Inc. for the development of antibodies targeting tumor-associated myeloid cells.

The company also collaborates with Transgene to jointly create innovative multi-functional oncolytic viruses aimed at solid tumors.

Additionally, a collaboration and supply agreement with Merck facilitates the clinical advancement of BI-1808. Founded in 1996, BioInvent International AB (publ) maintains its headquarters in Lund, Sweden.

Key Metrics
Market Cap$18.41M
Enterprise Value--
P/E Ratio--
Est. Net Cash/Share--
Institutional Ownership--

based on 65.80M shares outstanding

SectorHealthcare
IndustryBiotechnology
ExchangeOTC
CountrySESE
IPO Date-
Shares Outstanding65.80M
Authorized Shares
Float47.51M
52-Week Range
Volume
Average Daily Volume3.53K

30d Avg

3.53K

60d Avg

3.53K

90d Avg

3.53K

Earnings
Dividend History
No dividend history available